BBNX Stock Price, Chart, Stats & News

Beta Bionics, Inc.
Save
618.96M
Market cap
–
Current P/E
–
Forward P/E
BBNX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 55.40% |
Operating margin | -71.50% |
Pretax margin | -73.02% |
Net margin | -73.02% |
Effective tax rate | -0.00% |
ROA | -22.27% |
ROE | -24.45% |
D/E | 0.03x |
Interest coverage ratio | – |
BBNX valuation
P/E | – |
P/S | 4.76x |
P/B | 1.52x |
P/CF | -10.31x |
P/FCF | -10.45x |
P/OCF | -10.31x |
PEG | -1.03x |
EV multiple | -7.94x |
About
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.
Similar securities
Based on sector and market capitalization
Report issue











